End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.47 NZD | +1.71% | +7.68% | +20.64% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.97 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.64% | 9.83B | B+ | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.78B | A | ||
+1.43% | 50.66B | B- | ||
+11.60% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+3.03% | 26.3B | B | ||
+3.21% | 26.04B | A- | ||
+15.06% | 25.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FPH Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited